Navigation Links
Pebbles Along the 'Path' to Personalized Medicine
Date:6/22/2010

Panel discussion with Georgetown experts to address biotechnology, science, policy and ethical issues

WASHINGTON, June 22 /PRNewswire-USNewswire/ -- Earlier this week, the National Institutes of Health and the Food and Drug Administration outlined a "path" to accelerate and help ensure the safety of personalized medicine -- treatments tailored to match a person's genetic make-up.  Significant progress in this rapidly developing field will hinge on biotechnology and will be impacted by the law, healthcare policy and ethical issues.

On Wednesday, June 23rd, Georgetown University Medical Center will explore the many issues of personalized medicine with a special panel featuring experts from healthcare, bioethics, policy and law.

Panelists for the event include:

  • Howard J. Federoff, MD, PhD, executive vice president for health sciences; executive dean of Georgetown University School of Medicine
  • Kevin T. Fitzgerald, SJ, PhD, research associate professor in the Department of Oncology; Dr. David P. Lauler Chair in Catholic Health Care Ethics
  • Lawrence O. Gostin, faculty director of the O'Neill Institute for National and Global Health Law; Linda D. and Timothy J. O'Neill Professor of Global Health Law
  • Patrick Maguire, MD, PhD, president and CEO of Cyberheart, Inc.
  • Stephen R. Seiler, founder and CEO of AesRx LLC

*The event will be moderated by Maggie Little, PhD,  associate professor in the Department of Philosophy; director and senior research scholar at the Kennedy Institute of Ethics

Background of scientific experts:

Howard J. Federoff

Kevin T. Fitzgerald

Lawrence O. Gostin

Patrick Maguire

Stephen R. Seiler

Maggie Little

The presentation will take place at the Bethesda North Marriott Hotel & Conference Center (5701 Marinelli Road, Bethesda, MD, 20852) at 7:00 PM ET on June 23rd, 2010. Media interested in attending, please contact Tressa Iris Kirby, GUMC Communications Officer, by calling 202-687-8865 or emailing Tk275@georgetown.edu. A podcast of the discussion can be made available by request (24 hours prior to the event).

About Georgetown University Medical Center
Georgetown University Medical Center is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health). GUMC's mission is carried out with a strong emphasis on public service and a dedication to the Catholic, Jesuit principle of cura personalis -- or "care of the whole person." The Medical Center includes the School of Medicine and the School of Nursing and Health Studies, both nationally ranked, the world-renowned Lombardi Comprehensive Cancer Center and the Biomedical Graduate Research Organization (BGRO), home to 60 percent of the university's sponsored research funding.


'/>"/>
SOURCE Georgetown University Medical Center
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
4. Discussions With FDA on Pixantrone EXTEND (PIX301) Trial Provide Path for NDA Submission
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Reminder: XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
7. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. PATH, World Health Organization, and Partners Introduce Meningitis Vaccine in Burkina Faso
10. Epeius Biotechnologies Leads With Keynote Address on the Advent of Pathotropic Medicine for Cancer at the Global Pharma R&D Summit Conference in Boston MA
11. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... Supplyframe, the Industry Network for electronics ... Lab . Located in Pasadena, Calif., the Design Lab’s mission is to bring ... designed, built and brought to market. , The Design Lab is Supplyframe’s physical ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
(Date:6/23/2016)... YORK , June 23, 2016 ... trading session at 4,833.32, down 0.22%; the Dow Jones Industrial ... S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated ... INFI ), Nektar Therapeutics (NASDAQ: NKTR ), ... Therapeutics Inc. (NASDAQ: BIND ). Learn more about ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a ... designed, tuned and optimized exclusively for Okuma CNC machining centers at The International ... a collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics ...
Breaking Biology Technology:
(Date:5/3/2016)... , May 3, 2016  Neurotechnology, a ... the MegaMatcher Automated Biometric Identification System (ABIS) ... large-scale multi-biometric projects. MegaMatcher ABIS can process multiple ... using any combination of fingerprint, face or iris ... MegaMatcher SDK and MegaMatcher Accelerator , ...
(Date:4/28/2016)... 2016 First quarter 2016:   ... with the first quarter of 2015 The gross margin ... (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... unchanged, SEK 7,000-8,500 M. The operating margin for 2016 ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
Breaking Biology News(10 mins):